ASCO Annual Meeting

Patients with multiple myeloma were more likely to have no traceable amounts of disease left when Darzalex was added to a treatment regimen of Revlimid, Velcade and dexamethasone.

Survival outcomes and side effect rates were similar in patients with extensive-stage small cell lung cancer who did and did not have tiragolumab added to their treatment regimen of Tecentriq and chemotherapy.

Despite similar responses to treatment, patients with previously treated non-small cell lung cancer derived a better overall survival benefit from treatment with Keytruda combined with Cyramza than the usage of standard-of-care therapies.

At a follow-up of more than two years, treatment with a novel drug produced meaningful results in a group of patients with HER3-expressing metastatic breast cancer or metastatic triple-negative breast cancer.

The investigational agent SOT101 was safe and tolerable when given alone and in combination with Keytruda for patients with solid tumors.

Long-term study results show that outcomes, such as survival and response rates, in patients who have received Calquence-containing treatment regimens continue to outpace outcomes in those who were given Gazyva and chemotherapy.

Treatment with Trodelvy resulted in slight survival improvements, when compared with standard of care chemotherapy regimens, in patients with hormone receptor–positive, HER2-negative metastatic breast cancer.

Treatment with Lenvima plus Keytruda resulted in a 50% decrease in risk of disease progression or death compared with Sutent in patients with advanced kidney cancer.

Adcetris plus doxorubicin, vinblastine and dacarbazine is the first regimen to improve overall survival compared to the current standard of care for patients with advanced-stage classical Hodgkin lymphoma.

Tibsovo plus Vidaza led to survival benefit for patients with IDH1-mutant acute myeloid leukemia, according to findings from the AGILE clinical trial.

While Cabometyx had a favorable side effect profile, it did not lead to a significant survival advantage over placebo in a clinical trial.

Avasopasem manganese is the first drug that has been shown to reduce the incidence and severity of chemotherapy-related oral mucositis in patients with head and neck cancer, research showed.

Vonjo proved to have a similar, or superior, side effect profile compared with the best available therapy for patients with myelofibrosis, a form of blood cancer.

Adagrasib demonstrated an 80% disease control rate among patients with previously treated KRAS G12C–mutated non–small cell lung cancer.

The addition of nimotuzumab to a treatment regimen of the chemotherapy gemcitabine improved overall survival in patients with KRAS wild-type advanced pancreatic cancer.

Adding Imbruvica to a standard-of-care chemotherapy-immunotherapy treatment regimen was associated with a significant improvement in survival in older patients with newly diagnosed mantle cell lymphoma.

Research showed that Hispanic children with neuroblastoma who are participating on clinical trials tended to have worse survival outcomes than others.

A small percentage of patients with metastatic breast cancer participating in clinical trials in the U.S. are Black, which, according to a patient living with the disease is a huge concern since it doesn’t represent the general population.

An analysis of more than 25,000 patients with one of the more than 20 common cancers identified that even though telehealth use for cancer care increased during the COVID-19 pandemic, certain people were less likely to benefit from the easy access to care.

Results demonstrating the efficacy of Bavencio highlight the importance of incorporating recent clinical trial successes into the treatment conversation.

Opdivo was the first PD-1 inhibitor to show durable responses in patients with esophageal squamous cell carcinoma.

Treatment with pyrotinib and the chemotherapies trastuzumab, docetaxel and carboplatin significantly improved response rates over the triplet chemotherapy regimen alone in the neoadjuvant treatment of patients with HER2-positive breast cancer.

The data, according to the study’s lead author, confirm that Trodelvy should be considered a new standard of care in patients with metastatic triple-negative breast cancer.

Patients with early triple-negative breast cancer receiving Imfinzi in addition to neoadjuvant chemotherapy saw increased survival rates and complete responses to treatment.

The treatment was also associated with antitumor activity in patients with metastatic castration-resistant prostate cancer.

Responses to the study drug, according to one of the study’s authors, appeared far superior than what would have been expected with other treatments in patients with HER2-expressing metastatic colorectal cancer.

The long-term follow-up data, according to one of the study’s authors from the Sarah Cannon Cancer Institute, demonstrate “a new benchmark for the standard of care” in the treatment of patients with unresectable stage 3 non-small cell lung cancer.

Treatment with aumolertinib was associated with prolonged survival in patients with advanced non-small cell lung cancer.

After long-term follow-up, the CAR-T cell therapy still boosted survival outcomes in patients with relapsed/refractory multiple myeloma, regardless of the number of prior lines of therapy received.

Previously treated patients with non-small cell lung cancer tended to have better responses with Retevmo than they did with prior treatments.